The Use of Monoclonal Antibody-Based Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors in the Treatment of Hypercholesterolemia

In this review, we evaluated several studies in the literature to analyze the benefits and deleterious effects of the use of monoclonal antibodies (MABs)-based proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors in patients with hypercholesterolemia. Increased low-density lipoprotein ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Parikh, Riya R, Breve, Frank, Magnusson, Peter, Behzadi, Payam, Pergolizzi, Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Cardiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250913/
https://www.ncbi.nlm.nih.gov/pubmed/35795514
http://dx.doi.org/10.7759/cureus.25641

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250913/
https://www.ncbi.nlm.nih.gov/pubmed/35795514
http://dx.doi.org/10.7759/cureus.25641

Ejemplares similares